SG11201605699QA - FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX - Google Patents
FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEXInfo
- Publication number
- SG11201605699QA SG11201605699QA SG11201605699QA SG11201605699QA SG11201605699QA SG 11201605699Q A SG11201605699Q A SG 11201605699QA SG 11201605699Q A SG11201605699Q A SG 11201605699QA SG 11201605699Q A SG11201605699Q A SG 11201605699QA SG 11201605699Q A SG11201605699Q A SG 11201605699QA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- complex
- fused pyrimidines
- pyrimidines
- fused
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461929382P | 2014-01-20 | 2014-01-20 | |
PCT/US2015/011921 WO2015109285A1 (en) | 2014-01-20 | 2015-01-19 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605699QA true SG11201605699QA (en) | 2016-08-30 |
Family
ID=52478057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605699QA SG11201605699QA (en) | 2014-01-20 | 2015-01-19 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX |
Country Status (19)
Country | Link |
---|---|
US (2) | US9828363B2 (en) |
EP (1) | EP3097092B1 (en) |
JP (1) | JP6387111B2 (en) |
KR (1) | KR101922317B1 (en) |
CN (1) | CN106458996B (en) |
AR (1) | AR099138A1 (en) |
AU (1) | AU2015206292B2 (en) |
BR (1) | BR112016016421B1 (en) |
CA (1) | CA2936559C (en) |
CL (1) | CL2016001840A1 (en) |
EA (1) | EA031317B1 (en) |
ES (1) | ES2819867T3 (en) |
IL (1) | IL246692B (en) |
MX (1) | MX2016009465A (en) |
NZ (1) | NZ722624A (en) |
SG (1) | SG11201605699QA (en) |
TW (1) | TWI640516B (en) |
WO (1) | WO2015109285A1 (en) |
ZA (1) | ZA201605107B (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
US9828363B2 (en) | 2014-01-20 | 2017-11-28 | Cleave Biosciences, Inc. | Fused pyrimidines as inhibitors of P97 complex |
SG11201906223TA (en) * | 2016-12-22 | 2019-08-27 | Amgen Inc | Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer |
JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
ES2961253T3 (en) * | 2018-08-31 | 2024-03-11 | Mirati Therapeutics Inc | KRas G12C Inhibitors |
JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
US11236091B2 (en) | 2019-05-21 | 2022-02-01 | Amgen Inc. | Solid state forms |
CN110078749B (en) * | 2019-06-04 | 2021-01-01 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 3a, 3a' -difuran [2,3-b ] indoline compound, preparation method, pharmaceutical composition and application |
CN110872291B (en) * | 2019-11-26 | 2021-06-25 | 五邑大学 | Tetrahydropyridopyrimidine compound and preparation method and application thereof |
WO2021231322A1 (en) * | 2020-05-11 | 2021-11-18 | Cleave Therapeutics, Inc. | Crystalline forms and formulations of a vcp/p97 inhibitor |
JP2023526223A (en) * | 2020-05-11 | 2023-06-21 | クリーブ セラピューティクス,インク. | VCP/p97 inhibitors for cancer treatment |
GB202111193D0 (en) * | 2021-08-03 | 2021-09-15 | Phoremost Ltd | Pharmaceutical compounds |
WO2023086419A1 (en) * | 2021-11-10 | 2023-05-19 | Cleave Therapeutics, Inc. | Vcp/p97 inhibitor for the treatment of cancer |
CN116178374A (en) * | 2023-01-13 | 2023-05-30 | 河北医科大学 | Small-conductance calcium-activated potassium ion channel agonist, synthesis and application thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0640599T3 (en) | 1993-08-26 | 1998-09-28 | Ono Pharmaceutical Co | 4-aminopyrimidine derivatives |
WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
KR20010091827A (en) | 2000-03-18 | 2001-10-23 | 정상훈 | A remittance system via telecommunication terminal number and remittance method using the same |
KR20020020316A (en) | 2000-09-08 | 2002-03-15 | 라응찬 | Method for remitting money by internet service |
KR20030009830A (en) | 2001-07-24 | 2003-02-05 | 중소기업은행 | Apparatus and Methods for Cash Payment Service using a Mobile Terminal |
EP1352910A1 (en) | 2002-04-10 | 2003-10-15 | Grünenthal GmbH | New analogs of nitrobenzylthioinosine |
JP3862666B2 (en) | 2003-03-31 | 2006-12-27 | 株式会社みずほ銀行 | Banking processing method and banking processing program |
EP1663994B1 (en) * | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
CA2575180A1 (en) | 2004-08-03 | 2006-02-16 | Wyeth | Indazoles useful in treating cardiovascular diseases |
CA2609271C (en) | 2005-05-27 | 2014-02-25 | Proteolix, Inc. | Novel substrate for rpn 11 enzymatic activity |
WO2008040753A1 (en) * | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
AR063141A1 (en) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | DERIVATIVES OF 2- (BENZIMIDAZOLIL) PURINA 8- REPLACED FOR IMMUNOSUPPRESSION |
KR20100014271A (en) | 2006-11-16 | 2010-02-10 | 파마코페이아, 엘엘씨. | 7-substituted purine derivatives for immunosuppression |
WO2008085302A1 (en) | 2006-12-20 | 2008-07-17 | Merck & Co., Inc. | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
TWI496779B (en) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | Triazolopyridine compounds as pim kinase inhibitors |
EP2350076B1 (en) | 2008-09-22 | 2013-08-21 | Isis Innovation Ltd | Imidazo[1,2- alpha]pyridinyl bisphosphonates |
AU2009322836B2 (en) | 2008-11-25 | 2013-04-04 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
BRPI0920966B1 (en) | 2008-11-28 | 2022-03-03 | Kowa Company Ltd | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE, ITS USE, JAK3 INHIBITOR AND PHARMACEUTICAL COMPOSITION |
AR074870A1 (en) | 2008-12-24 | 2011-02-16 | Palau Pharma Sa | DERIVATIVES OF PIRAZOLO (1,5-A) PIRIDINA |
CN102459272B (en) | 2009-05-27 | 2014-08-06 | 健泰科生物技术公司 | Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
UY33213A (en) | 2010-02-18 | 2011-09-30 | Almirall Sa | PIRAZOL DERIVATIVES AS JAK INHIBITORS |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
JP2013530942A (en) * | 2010-05-07 | 2013-08-01 | カリフォルニア・インスティチュート・オブ・テクノロジー | Methods and compositions for inhibition of transitional endoplasmic reticulum ATPase |
JP2013166700A (en) | 2010-06-02 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | Novel 4, 5-fused pyrimidine derivative |
RU2673064C2 (en) | 2011-09-01 | 2018-11-22 | Ф. Хоффманн-Ля Рош Аг | Pyrrolopyrazine kinase inhibitors |
WO2013170770A1 (en) | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | Acetylene derivatives having antitumor activity |
WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
BR112015001213A2 (en) | 2012-07-20 | 2018-05-22 | Cleave Biosciences Inc | fused pyrimidines as p97 complex inhibitors |
WO2015089218A1 (en) | 2013-12-10 | 2015-06-18 | David Wustrow | Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex |
CN116987172A (en) | 2014-01-20 | 2023-11-03 | 韩美药品株式会社 | Long acting insulin and uses thereof |
US9828363B2 (en) | 2014-01-20 | 2017-11-28 | Cleave Biosciences, Inc. | Fused pyrimidines as inhibitors of P97 complex |
-
2015
- 2015-01-19 US US15/112,659 patent/US9828363B2/en active Active
- 2015-01-19 EP EP15705122.8A patent/EP3097092B1/en active Active
- 2015-01-19 JP JP2016565125A patent/JP6387111B2/en active Active
- 2015-01-19 EA EA201691472A patent/EA031317B1/en not_active IP Right Cessation
- 2015-01-19 BR BR112016016421-0A patent/BR112016016421B1/en active IP Right Grant
- 2015-01-19 AU AU2015206292A patent/AU2015206292B2/en active Active
- 2015-01-19 CN CN201580014762.XA patent/CN106458996B/en active Active
- 2015-01-19 SG SG11201605699QA patent/SG11201605699QA/en unknown
- 2015-01-19 CA CA2936559A patent/CA2936559C/en active Active
- 2015-01-19 KR KR1020167022764A patent/KR101922317B1/en active IP Right Grant
- 2015-01-19 NZ NZ722624A patent/NZ722624A/en unknown
- 2015-01-19 WO PCT/US2015/011921 patent/WO2015109285A1/en active Application Filing
- 2015-01-19 MX MX2016009465A patent/MX2016009465A/en active IP Right Grant
- 2015-01-19 ES ES15705122T patent/ES2819867T3/en active Active
- 2015-01-20 TW TW104101853A patent/TWI640516B/en active
- 2015-01-20 AR ARP150100150A patent/AR099138A1/en active IP Right Grant
-
2016
- 2016-07-10 IL IL246692A patent/IL246692B/en active IP Right Grant
- 2016-07-20 CL CL2016001840A patent/CL2016001840A1/en unknown
- 2016-07-21 ZA ZA2016/05107A patent/ZA201605107B/en unknown
-
2017
- 2017-10-24 US US15/792,514 patent/US10174005B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA031317B1 (en) | 2018-12-28 |
CA2936559A1 (en) | 2015-07-23 |
WO2015109285A1 (en) | 2015-07-23 |
CN106458996A (en) | 2017-02-22 |
EP3097092A1 (en) | 2016-11-30 |
JP2017505812A (en) | 2017-02-23 |
ZA201605107B (en) | 2017-09-27 |
CN106458996B (en) | 2020-11-03 |
AU2015206292A1 (en) | 2016-08-18 |
US9828363B2 (en) | 2017-11-28 |
IL246692A0 (en) | 2016-08-31 |
AU2015206292B2 (en) | 2018-02-15 |
KR101922317B1 (en) | 2018-11-26 |
EA201691472A1 (en) | 2017-05-31 |
CA2936559C (en) | 2019-03-12 |
TWI640516B (en) | 2018-11-11 |
KR20160110506A (en) | 2016-09-21 |
US20180044325A1 (en) | 2018-02-15 |
CL2016001840A1 (en) | 2017-04-17 |
JP6387111B2 (en) | 2018-09-05 |
EP3097092B1 (en) | 2020-08-26 |
MX2016009465A (en) | 2016-12-02 |
US20160332990A1 (en) | 2016-11-17 |
US10174005B2 (en) | 2019-01-08 |
TW201605833A (en) | 2016-02-16 |
BR112016016421B1 (en) | 2022-10-18 |
BR112016016421A2 (en) | 2017-08-08 |
ES2819867T3 (en) | 2021-04-19 |
NZ722624A (en) | 2017-09-29 |
IL246692B (en) | 2019-05-30 |
AR099138A1 (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201605107B (en) | Fused pyrimidines as inhibitors of p97 complex | |
IL251584B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL246902B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
GB201511567D0 (en) | Superhard constructions & methods of making same | |
GB201421083D0 (en) | Enzyme inhibitors | |
GB201421088D0 (en) | New enzyme inhibitors | |
EP3183255C0 (en) | Spiropyrrolidines as mdm2 inhibitors | |
GB201421085D0 (en) | New enzyme inhibitors | |
GB2531657B (en) | Superhard constructions & methods of making same | |
GB2533866B (en) | Superhard constructions & methods of making same | |
EP3102571A4 (en) | Substituted pyrimidines useful as egfr-t790m kinase inhibitors | |
GB201504576D0 (en) | Superhard constructions & methods of making same | |
GB201423405D0 (en) | Superhard construction & methods of making same | |
HK1244790A1 (en) | Bace1 inhibitors | |
IL248999A0 (en) | Method of geolocation | |
GB201523147D0 (en) | Superhard constructions & methods of making same | |
GB201418230D0 (en) | Construction of surfaces | |
GB201423408D0 (en) | Superhard constructions & methods of making same | |
GB201423412D0 (en) | Superhard constructions & methods of making same | |
HUP1400294A2 (en) | Novel application of clopidogrel | |
GB201417601D0 (en) | Articles of manufacture | |
GB201412053D0 (en) | Articles of manufacture | |
GB201405158D0 (en) | Theory of european law | |
GB201404705D0 (en) | Theory of Conceptual art | |
GB201405157D0 (en) | Theory of international law |